谁“知道”呢，会是血管紧张素受体脑啡肽酶抑制剂吗？：一组接受沙库巴曲缬沙坦治疗的心力衰竭患者持续性鼻痒病例系列。
Who 'nose', is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan.
作者信息
Gan Jaclyn, Rheault Haunnah, Wong Yee Weng
机构信息
Heart Lung Institute, The Prince Charles Hospital, Rode Road, Chermside, Queensland 4032, Australia.
Pharmacy Department, The Prince Charles Hospital, Rode Road, Chermside, Queensland 4032, Australia.
出版信息
Eur Heart J Case Rep. 2021 Dec 11;5(12):ytab506. doi: 10.1093/ehjcr/ytab506. eCollection 2021 Dec.
BACKGROUND
Sacubitril/valsartan is approved for the treatment of chronic heart failure with reduced left ventricular ejection fraction of ≤40% to decrease mortality and morbidity. Nasal pruritus is not a recognized adverse effect in the product information. In this case series, we encountered three patients who presented with nasal pruritus that improved after discontinuation of sacubitril/valsartan.
CASE SUMMARY
Three patients aged 58-73 years-old presented with pruritus at the nasal septum post-initiation of sacubitril/valsartan. The pruritus did not subside despite the use of anti-histamines. Within 3-6 months, all individuals discontinued sacubitril/valsartan with complete resolution of their nasal pruritus.
DISCUSSION
Many physicians may not aware of this unusual but reversible adverse effect of sacubitril/valsartan. Despite the positive prognostic value of sacubitril/valsartan, the constant nasal pruritus had impacted the quality of life of our patients, leading them to discontinue sacubitril/valsartan permanently.
背景
沙库巴曲缬沙坦已被批准用于治疗左心室射血分数降低至≤40%的慢性心力衰竭，以降低死亡率和发病率。鼻痒在产品说明书中并非公认的不良反应。在本病例系列中，我们遇到了三名患者，他们在出现鼻痒症状后停用沙库巴曲缬沙坦，症状得到改善。
病例总结
三名年龄在58至73岁之间的患者在开始使用沙库巴曲缬沙坦后出现鼻中隔瘙痒。尽管使用了抗组胺药，瘙痒仍未消退。在3至6个月内，所有患者均停用沙库巴曲缬沙坦，鼻痒症状完全缓解。
讨论
许多医生可能并未意识到沙库巴曲缬沙坦这种不常见但可逆的不良反应。尽管沙库巴曲缬沙坦具有积极的预后价值，但持续的鼻痒影响了我们患者的生活质量，导致他们永久停用沙库巴曲缬沙坦。
Zotero 插件